Introduction
The prevalence of diabetes mellitus continues to increase with approximately 12.9% of the population in the United States diagnosed with diabetes and an even larger portion (29.5%) estimated to be living in a prediabetic state. 1 Control of blood glucose (BG) in an acceptable range remains a target for diabetes patients in both the hospital and outpatient environments. 2 Glycemic control using an insulin infusion in critically ill patients requires frequent and rapid BG monitoring with devices available for bedside use. [3] [4] [5] [6] [7] The accuracy of the BG measurements plays an important role for treatment decisions when aiming for glycemic control. This article reviews the accuracy and limitations of current point-of-care glucose monitoring devices (POCGMDs).
Glucose Oxidase
This measurement technique uses glucose oxidase (GOX) as a catalyst for oxidation of glucose to gluconic acid and hydrogen peroxide; the amount of hydrogen peroxide produced is proportional to the glucose concentration in the blood sample. This change in the hydrogen peroxide concentration can be measured by using a color change as an indicator using a photometric technique or in newer devices, which rely on the production of an electrical current (amperometric technique). 8 The basic chemical pathways for the GOX reactions are shown in Figure 1 .
Glucose-1-dehydrogenase
This measurement technique uses glucose-1-dehydrogenase (GDH) to convert glucose to gluconolactone with older devices using a coenzyme to convert nicotinamide adenine dinucleotide (NAD) to NADH (reduced form of NAD). The NADH concentration is measured and is proportional to the BG concentration. The NADH concentration can be measured using a photometric or amperometric technique. Newer POCGMDs use the coenzyme pyrroloquinoline quinone (PQQ) because of less sensitivity to ambient oxygen and electrochemical interference. However, this coenzyme has introduced a dangerous situation, as described later. The outline for the GDH PQQ reaction is shown in Figure 1 . Both GOX and GDH measurement techniques present limitations. The GOX method is extremely specific for BG concentration. However, blood oxygen concentrations influence GOX devices, but not the GDH technique. 9, 10 The potential influence of physically dissolved oxygen for the GOX reaction is shown in Figure 1 . When there are high levels of dissolved oxygen in the sample (e.g., hyperoxia), oxygen is readily available for the GOX reaction and can cause an underestimation of blood glucose; conversely, hypoxemia may falsely elevate GOX glucose measurements. The significance of the oxygen influence is relatively small compared to other potential interferences. 9, 11 The GDH technique using PQQ has limitations as well. This coenzyme reacts with other sugars (e.g., maltose, galactose, mannose, xylose, and ribose) and detects them as glucose; alternate techniques should be used when these other sugars are present. 12, 13 The Food and Drug Administration (FDA) issued a public health notification in 2009, secondary to a number of deaths, for the use of the GDH-PQQ glucose monitor because of the potential fatal error related to the interference of other sugars with this methodology.
14 For example, icodextrin (a substance commonly used in peritoneal dialysis fluid) is broken down to maltose, which is reported as glucose with the GDH-PQQ POCGMDs. Because of this substance interference, the POCGMD overreports the BG level and, in some cases, can lead to critical treatment errors with significant consequences of hypoglycemia.
Drugs may interfere with both GOX and GDH glucose measurement methods, including but not limited to ascorbic acid and acetaminophen. 15, 16 The presence of high doses of ascorbic acid has the potential to read falsely low in GOX-and GDH-based devices. Acetaminophen, in therapeutic concentrations, results in lower and higher glucose measurements with the GOX and GDH POCGMD techniques, respectively.
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Central Laboratory Devices
One comparison used for glucose devices is the central laboratory device (CLD) because of its higher accuracy, and studies assessing POCGMD accuracy often employ CLD. Measurement techniques of CLDs vary by device type, and most frequently utilize either the GOX or, more commonly, the glucose hexokinase reaction to measure BG concentration. According to a proficiency report surveying U.S. laboratories, the majority of CLDs use a hexokinase-based method, and the remaining facilities use GOX-based assays. 17 Glucose hexokinase phosphorylates glucose to glucose-6-phosphate which is then oxidized by glucose-6-phosphate dehydrogenase using NAD as a cofactor. This results in production of NADH, and the concentration is measured with a spectrophotometer (absorption 340 nm) to determine BG concentration.
The YSI (Yellow Springs Instruments, Yellow Springs, OH) has been used in many studies as a glucose reference. The YSI uses GOX to measure the hydrogen peroxide produced with an amperometric technique. However, in clinical practice, the YSI analysis has been replaced by multianalyte automated instrumentation. Rarely, a radioactive labeled isotope assay is used for instrument validation. Few laboratories still report YSI values.
17,18
Sample Source and Collection Site
Methodologies involved with the collection site and storage can significantly impact BG measurements. At room temperature, glucose is metabolized by blood cells at a rate of 5-7% per hour. 19 Glycolysis is typically not an issue for a POC measurement, but can cause falsely lower values in CLD results with delayed analysis. One should be cognizant of this when comparing results from both sources.
The CLD reports plasma glucose concentrations; POCGMD measurements typically involve whole blood samples with results usually internally converted to plasma values. Glucose concentrations are higher in the plasma than whole blood because the water content (and thus the glucose concentration) is higher in plasma than in erythrocytes. 20 The water content of the plasma can be affected by the concentration of other components. Hypertriglyceridemia and paraproteinemias decrease the water concentration in the whole blood sample, potentially causing a "pseudohypoglycemia," measured by POCGMDs. 20 Sample source can also significantly impact glucose concentration measurements. Potential sampling sites include arterial, venous, or capillary (e.g., finger tips, ear lobes, etc.). As a general rule, the highest to lowest glucose concentration by sampling site is artery, capillary, and then venous. 21 The difference in glucose concentrations between capillary and venous blood can be altered by the patient's metabolic state, with insignificant differences in the absence of stress and fasting. In a critically ill patient, the presence of a hypermetabolic state and other stressors, including fasting, can cause significant differences between these values. 21, 22 As an example, a critically ill patient with circulatory shock may exhibit a significant difference caused by increased glucose extraction and poor tissue perfusion.
Blood oxygenation affects POCGMD glucose measurement techniques with GOX and not with GDH. [9] [10] [11] Although values may not differ significantly within the normal oxygen range, errors with GOX measurement techniques can be 15% or more when P a O 2 (blood oxygen content) exceeds 100 mm Hg or falls below 44 mm Hg depending on the type of test strip and measurement method. 9, 23 As shown in Figure 1 , GOX test strips using peroxide/meta[3-methyl 2 benzothiazoline hydrazine] N-sulfonyl benzene sulfonic acid (MBTH) are less vulnerable to oxygen presence than the GOX/ferrocene method. On the basis of a comparative analysis of several POC test strips by Tang and colleagues, 11 using ±15% of reference value from CLD as tolerated error, the GOX/ ferrocene strips had the highest glucose measurements outside of the error tolerances (20.1-31.6%), while 14.3% of the GOX/MBTH measurements were outside of the set limits. The impact of oxygen tension on accuracy worsened when blood glucose concentration fell below 100 mg/dl and the oxygen tension was above 100 mm Hg. Only one study investigated the influence of extremely low oxygen tension on POC glucose measurements and found that GOX-based techniques might be inaccurate at extremely low oxygen tensions (PO 2 less than 20 mm Hg). 23 Although the impact of oxygen tension on the overall accuracy of POCGMD in the cited studies can be minimal, it is not negligible. Therefore, it has been recommended to minimize the oxygen tension effect on glucose testing variability by using oxygen-insensitive test methods in critically ill patients with P a O 2 >100 mm Hg or patients with unpredictable blood PO 2 levels. 11 The impact of patient factors on POC glucose accuracy has been investigated by assessing POCGMDs during tight glycemic control for critically ill patients. The application of POCGMDs for glucose monitoring in critically ill patients is thus important with a detailed discussion covered later in this review. The FDA MAUDE (Food and Drug Administration Manufacturer and User Facility Device Experience) database has been searched for reports related to glucose monitors, revealing 189 records for the year 2011. 24 An inquiry of the FDA recall database indicated 30 recalls related to glucose monitors in the time frame 2004-2011. 24 Based on the review of the databases mentioned earlier, the POCGMD technology is not always the cause of inaccuracy. Additional effects can come from sample sources, collection sites, and patient factors, and may include the glucose meter cleaning solution or the disinfectant wipe interfering with the measurement.
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Point-of-Care Glucose Monitoring Devices Accuracy
There are two ways to assess the accuracy of glucose measurement techniques: technical or clinical. Technical accuracy assesses the agreement between the measured and reference glucose values. Clinical accuracy judges how the differences in the measurements impact clinical decision processes. Both have clinical implications.
A review by Krouwer and Cembrowski 27 details the standards and statistical methods used to characterize accuracy of POCGMDs and highlight the different criteria acceptable for accuracy between standard organizations and professional societies ( Table 2) . In 1987, an American Diabetes Association (ADA) consensus statement recommended that the acceptable error for POCGMDs from all sources (user, analytical, etc.) should be less than 10% for glucoses ranging from 30 to 400 mg/dl at all times.
This ADA consensus statement also recommended that glucose measurements should not differ more than 15% from values obtained by a laboratory reference method. The ADA decreased the maximum allowable analytical error to <5% in 1996. 29, 30 International Organization for Standardization (ISO) 15197 provided different recommendations in 2003. 31 These state that 95% of the individual glucose measurements compared to the reference measurements are required to be in the range ±15 mg/dl for values less than or equal to 75 mg/dl and ±20% for glucose values greater than 75 mg/dl. 30 This is the standard that the FDA normally uses as the goal for approval of POCGMDs. The standards set by the ADA (ADA 1987 (ADA /1996 , requiring all glucose measurements with POCGMDs to be within 5% of CLD values, were deemed technically unachievable by the International Federation of Clinical Chemistry and Laboratory Medicine. 19, 27 Additionally, the ranges of error set by the technical standards and allowable error do not address the possibility that these errors might provide safety concerns for patients by decision-making being based on inaccurate glucose values. 19, 31, 32 Because of these concerns, publications have reviewed the technical and statistical aspects of POCGMD glucose monitoring. 20, 27, 33, 34 Several statistical and graphical options has been used to correlate POCGMD measurements with CLD values. One option to assess analytical error is to use bias plots, such as Bland-Altman (BA) plots. The BA plot graphs the difference between a candidate and a reference method plotted against the mean of the two measurements, where the candidate method is the method under validation. Therefore, the BA plot is a direct visualization of the difference between the two methods. Bias plots allow the analysis of bias and variation from reference of POCGMD measurement over a range of glucose concentrations. 35 However, information about the clinical significance of the error is not included in this type of analysis. The error grid plots accuracy in terms of the effect on clinical decisions. The recognized need for a more clinically oriented approach to ensure patient safety for evaluation and regulation accuracy of devices was addressed by Clarke and colleagues 36 in 1987, with these recommendations modified by Parkes and colleagues 37 in 2000, which is commonly called the consensus grid. Clarke and colleagues 36 developed the error grid to evaluate the accuracy of the clinical decision-making based on the measured glucose value. The grids define several zones: zone A, points with no clinical implication because of clinically accurate measurement; zone B, points still lead to accurate clinical decisions; zone C, 2 and 3) because of concerns of the proximity of the results in zone A (acceptable result) and zone D (dangerous result). Although the error grids of Clarke and Parkes have been used to explore the clinical accuracy and implications of POCGMDs, organizations responsible for establishing standards have yet to adopt this approach. The FDA commonly uses error grids in the approval process for a POCGMD.
On the basis of recent publications reviewing the difficulties of the technical and statistical aspect of POCGMD glucose monitoring, the currently available standards are not meeting the needs of clinicians in certain environments (hyper-or hypoglycemia, intensive insulin therapy), and clinicians are concerned with the lack of agreement between POCGMD results with serum/ plasma laboratory results. 20, 27 With concerns that the current allowable errors could potentially harm patients, there has been a call for the development of more clinically relevant standards. 20, 27, 33, 34 Studies of Point-of-Care Glucose Monitoring Devices Accuracy A Medline search was performed for the years 1990-2011 using the following key words: blood glucose, glucose meter, glucose error, glucose measurement, hypoglycemia, point-of-care device, tight glucose control, and insulin therapy. Review of this literature identified publications relevant to the evaluation of POCGMD accuracy. Characteristics of the relevant publications studying outpatients or hospitalized ward patients excluding intensive care unit (ICU) patients are listed in Table 3 , with a study summary in Table 4 . This search revealed publications that compared several POCGMDs to a reference CLD. Giordano and colleagues 38 compared seven commercially available POCGMDs with a reference method, finding only three devices had acceptable measurement accuracy. The remaining four devices consistently underestimated blood glucose levels of less than 100 mg/dl, raising concerns about the potential implications of unrecognized and thus untreated hypoglycemia. Chen and colleagues 39 blindly evaluated four POCGMDs to prevent any potential bias created by commercial pressure. Only two out of four devices performed with acceptable accuracy according to ISO standards; none achieved the ADA 1996 recommendations for POCGMD accuracy. All four POCGMDs showed less reliability with lower glucose values compared to normal or higher values. Cohen and colleagues 40 evaluated five POCGMD using the Clarke error grid; four of the five devices met criteria for accurate clinical decision-making. However, only one out of five devices met ADA 1996 accuracy standards.
Seven POCGMDs involving four different manufacturers were compared to a reference method (YSI) by Khan and colleagues. 41 Only one device met ADA 1996 performance requirements. Of major concern was the significant disagreement with reference values within the critical hypoglycemic range that could result in an adverse clinical decision. At the extremes of hyperglycemia and hypoglycemia, when compared to CLD, 61% of values differed by more than 10% from the reference method with an alarming 57% of measurements differing by more than 20% in the hypoglycemic range. This study emphasizes the shortcomings for accurate detection and thus treatment of hypoglycemia with POCGMDs.
In 2008, Thomas and colleagues 42 evaluated several POCGMDs not available in the United States. Four of the five devices were deemed accurate enough to be used in a clinical setting based on a Clarke error grid. However, only two of the five devices provided measurements with less than 20% variation from the reference method, with one device having less than 10% error.
Although the ADA and ISO guidelines have been published for over a decade, few POCGMDs meet these accuracy standards. Two examples of evaluations include (1) Sheffield and colleagues 43 studied four commercially available POCGMDs and reported that only two devices met ISO standard requirements and (2) Florkowski and colleagues 44 evaluated two POCGMDs, and although both passed ISO requirements, they failed to meet ADA 1996 recommendations.
One specific concern with POCGMDs is errors in the hypoglycemic range and the potential impact on clinical decision-making. When errors occur in the lower glucose ranges, it most commonly entails a report of a higher than actual blood glucose value. This can lead to a misdiagnosis of euglycemia when in fact hypoglycemia exists, placing the patient at risk for neurological sequelae because of a failure of early recognition or aggressive treatment of hypoglycemia. 38, 39, 41, [45] [46] [47] [48] [49] [50] Because of the importance of accurate glucose values in the hypoglycemic range, Stork 46 focused further evaluation of POCGMDs in these patients. While measurements in the euglycemic range were acceptable, measurement accuracy decreased significantly in the hypoglycemic range. In neonates, POCGMDs for hypoglycemia screening did not have the required accuracy. 47, 50 Although less frequent, POCGMDs can report a falsely low value. The error may result in treatment for hypoglycemic when, in fact, euglycemia actually exists; the hypoglycemia treatment with additional glucose may lead to hyperglycemia. These examples illustrate some of the limitations of current POCGMDs. The accuracy of POCGMDs in these studies rarely met ADA accuracy recommendations in the hypoglycemia range. These devices were originally designed for outpatient SMBG, not to accurately reflect hypoglycemia in hospitalized ward and critically ill patients, whose condition may mask signs and symptoms of hypoglycemia. 
Studies of
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BGlu within 10% of RM = 48%, Clarke A 67, B 26, C 1, D 6 (All POCGMD had a tendency to read higher at low BGlu level)
Sheffield et al. 43 Optium 42% of BGlu varied <5% of RM, precision 9 ± 10 mg/dl Optium was found to be the most accurate POCGMD with 94% of BGlu were in <20% agreement with RM. Only Optium and DDI Prodigy met ISO accuracy criteria BGlu, blood glucose concentration; RM, reference method; GOX, glucose oxidase method; HCP, health care provider; R, regression coefficient; CI, confidence interval; CV, coefficient of variation.
agents, that interfere with POCGMD. Other factors that may impact accuracy of testing include significant variation in hematocrit (Hct), pH, and blood oxygen or carbon dioxide level. Hyperglycemia treatment for many critically ill patients requires intravenous insulin infusion to control blood glucose. 6, 7, 59, 60 Accurate BG measurements are extremely important for patients on insulin infusions. Relevant publications of POCGMD evaluated in the critically ill patient are listed in Table 5 .
The impact of Hct on the POCGMD accuracy in critically ill patients has received attention. Some studies documented the influence 16 ,51,52,57,61-64 of Hct variation, especially when acute anemia develops in certain patient populations (e.g., cardiac surgery), 61, 62, 64 while others report accuracy over a wide range of Hcts. 51, 52, 63 Newer POCGMDs correct for Hct variation with several amperometric methods, involving a new technique called dynamic electrochemistry. 65, 66 There are certainly numerous possible interferences with these techniques, which may be similar to those recently documented for Hct POC measurements, which use similar methodology. 67 Blood oxygen content (P a O 2 ), carbon dioxide tension (P a CO 2 ), and blood pH changes all can impact glucose measurement accuracy. Dissolved blood oxygen can interfere with the GOX assay as previously detailed. 9, 11, 23 All POCGMD methods rely on enzymatic activity with function potentially affected by changes in blood pH and P a CO 2 . Louie and colleagues 62 studied the influence of P a O 2 , P a CO 2 , and pH with POCGMDs using GOX and GDH technology. Neither POCGMD using GOX or GDH technology were affected by P a CO 2 or pH, and the POCGMD using GDH was unaffected by P a O 2. However, the GOX POCGMD was sensitive to oxygen tension, consistently reporting lower than actual BG value when P a O 2 levels exceeded 150 mm Hg. However, Lacara and colleagues, 63 using a multifactorial regression model in a small patient population (n = 42 patients), found that plasma P a CO 2 contributed to the difference between CLD and POC glucoses in critically ill patients after Hct correction. In summary, the influence of carbon dioxide tension on the POCGMD accuracy remains controversial and is most likely minimal.
The influences of peripheral edema, hypotension, vasopressor, or catecholamine therapy on POCGMD accuracy in critically ill patients had been the subject of several investigations. 21, 63, [68] [69] [70] [71] [72] [73] Kanji and colleagues 68 investigated the influences of peripheral edema and vasopressor therapy on POC glucose monitoring. Disagreement was defined when CLD and POCGMD results led to different treatment decisions based on an institutional insulin therapy protocol. Compared to arterial sampling, capillary sampling was less accurate for glucose measurements in critically ill patients, especially in the hypoglycemia range. 68, 70 With fast changing BG values, the time constant for capillary blood may be quite long and could be a contributor to inaccuracy under these circumstances. 74 Fewer than 80% of the capillary samples were in agreement with the CLD measurement. When hypotension was present, this agreement further decreased to less than 70%. With the presence of edema or when patients were receiving vasopressor medications and BG levels were <80 mg/dl, only 25% of the capillary POCGMD measurements and less than 55% of arterial POCGMD measurements were accurate when compared with CLD results (Figure 4) . 68 Focusing on patients with low perfusion indices and requiring vasopressor therapy, Desachy and colleagues 71 noted disagreement between POCGMD and CLD in more than 15% of capillary samples. These measurement discrepancies correlated with low tissue perfusion index, generalized mottling, and hypotension. These influences were noted in older investigations by Atkin et al. 22 and Sylvain et al., 73 where hypotensive patients' capillary blood glucose values were inaccurate. The time constant of the capillary blood space may contribute to this discrepancy, as lower perfusion may lengthen the time constant. Catecholamine administration to critically ill patients also influences POC glucose. Fekih-Hassen and colleagues 72 investigated the accuracy of two capillary sampling sites in critically ill patients being administered catecholamines compared to hemodynamically stable patients not receiving these drugs. In critically ill patients receiving catecholamines, the POCGMD and CLD measurements differed from 29% to 40%. Even in hemodynamically stable patients, there was less than acceptable POCGMD accuracy with capillary sampling. 72 When comparing the performance of three POCGMDs in critically ill patients compared with noncritically ill patients, Hoedemaekers and colleagues 78 found all three devices to be less accurate in the critically ill patients. When inaccurate, the POC glucose levels were most often falsely elevated, with the potential for inappropriate insulin administration and/or masking "true hypoglycemia." The use of insulin infusions to manage BG levels in critically ill patients demands monitoring to be precise, reliable, and frequent.
Several studies have investigated POCGMDs during intensive insulin therapy in critically ill patients. 70, 76, 78 Capillary samples in one study showed acceptable accuracy during intensive insulin therapy in normotensive and euglycemic patients after cardiac surgery. 76 Two other studies found POCGMDs to have significant inaccuracies in critically ill patients. 70 70 because of the variable time constant in the capillary sample, and the use of different sites might explain some discrepancies in POCGMD compared to CLD. When initiating intensive insulin therapy, close attention should be paid to potential sources of error, including sample source, measurement techniques, and patient factors. All these factors should be taken into consideration when making treatment decisions. Blood glucose concentration should be measured frequently (at minimum hourly) during intensive insulin therapy in critically ill patients, and when values obtained from POCGMD pose a patient safety risk, those values should be confirmed by CLD.
Conclusion
Accuracy can be defined as the variation from the reference value. When assessing laboratory values for glucose, the testing method is accurate if the measurement is within acceptable error compared to the reference method. Within the range of hypoglycemia, if the values reported by the POCGMD are inaccurate (e.g., reported higher than actual values), this inaccuracy could lead to failure to recognize and treat life-threatening values or even Figure 4 . POCGMD glucose measurement agreement with reference method during hypoglycemia versus nonhypoglycemia in critically ill patients. The POCGMD glucose measurement were said to agree with the reference method (CLD) if both measurements resulted in a similar clinical intervention. A total of 118 paired observations were analyzed (all), divided into three groups: vasopressor-dependent (n = 36: hypoglycemia n = 8, nonhypoglycemia n = 28), edematous (n = 43: hypoglycemia n = 21, nonhypoglycemia n = 22), and postsurgical (n = 39: hypoglycemia n = 9, nonhypoglycemia n = 30). Data are presented as mean with 95% confidence interval. For the statistical analysis, please review the original data source. more worrisome result in a different treatment (e.g., increasing insulin infusions) that could pose a serious patient safety risk. The importance of accuracy for clinical treatment assesses whether the measurement value is within a range close enough to the actual value that the clinical approach to therapy remains the same. The current ADA device recommendations for SMBG with POCGMDs include the following: (a) achieve and maintain glycemic control, (b) prevent and detect hypoglycemia, (c) avoid severe hyperglycemia, and (d) facilitate diabetes therapy adjustment to lifestyle changes (activity, diet changes, etc.). The accuracy requirements set by the professional organizations are still rarely met by POCGMDs. With outpatients and other hospitalized noncritically ill patients, most clinicians appear satisfied with POCGMD accuracy when glucose values avoid the extremes of hypoglycemia and hyperglycemia. This is because, in the range of normal glucose, the accuracy in this range is typically acceptable for clinical decisionmaking. For the care of critically ill patients, accuracy becomes more important as some of the early signs present with hypoglycemia and hyperglycemia may be difficult to detect in this patient population due to decreased mental status, sedatives, and other patient conditions. For optimal glucose control in high-demand states in critically ill patients, POCGMD technology has yet to provide a high enough degree of accuracy and reliability that leads to appropriate clinical decision-making. Continuous glucose monitoring devices based on invasive, minimal invasive, or noninvasive methodology are being developed to improve blood glucose monitoring. 82 Available technology, including future advances and current limitations, has been reviewed by Vaddiraju and colleagues. 83 Development of a meter with accuracy equal to CLDs should continue to be the industry goal.
